Zacks: IsoRay, Inc. (ISR) Given Consensus Rating of “Buy” by Brokerages

IsoRay, Inc. (NASDAQ:ISR) has been assigned a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. IsoRay’s rating score has improved by 25.1% from 90 days ago as a result of a number of analysts’ ratings changes.

Analysts have set a 12 month consensus price objective of $0.85 for the company and are predicting that the company will post ($0.02) EPS for the current quarter, according to Zacks. Zacks has also given IsoRay an industry rank of 39 out of 255 based on the ratings given to related companies.

Separately, HC Wainwright reiterated a “buy” rating on shares of IsoRay in a report on Monday, January 28th.

ISR remained flat at $$0.39 during trading on Friday. 43,469 shares of the company traded hands, compared to its average volume of 171,741. IsoRay has a 1 year low of $0.27 and a 1 year high of $1.22.

IsoRay (NASDAQ:ISR) last posted its quarterly earnings results on Tuesday, February 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). The company had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.76 million.

About IsoRay

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

See Also: Swap

Get a free copy of the Zacks research report on IsoRay (ISR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.